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The 5-year survival rate of primary anorectal malignant melanoma is less than 20%. 
Optimal treatment of this condition remains controversial regarding locally disease, and 
whether any preferential survival benefit arises from either abdominoperineal resection 
or wide local excision remains unknown. The majority of patients progress to metastatic 
disease, and for decades, the use of chemotherapies, such as platines or dacarbazine, 
has been advocated to improve overall survival. The therapeutic use of new checkpoint 
inhibitors in a variety of trials has provided evidence for an antitumoral effect of PD-1 
and/or CTL4 inhibitors in mucosal melanomas, but these treatments must still be further 
evaluated. Some anecdotal occurrences of rapid progression [i.e., hyperprogressive 
disease (HPD)] while using these immune agents have been described, suggesting 
potentially deleterious effects of these drugs for some patients. We report a 77-year-old 
male metastatic anorectal melanoma patient presenting with HPD over 2 months of a 
PD1 inhibitor treatment course and document this HPD blood phenotype.
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INtRoDUCtIoN
Anorectal malignant melanomas (ARMM) comprise approximately 1% of all melanomas and 
approximately 0.5–2% of all anorectal malignancies (1). It affects the anal canal, rectum, and inter-
mediate sites in equal proportions (2). The median overall survival after diagnosis is between 8 
and 19 months (3), and the 5-year survival is 20 and 0% in cases of locoregional resectable disease 
and advanced disease, respectively (4). A poor overall survival in ARMM is associated with male 
gender, perineural invasion, infiltration depth of the rectal wall, lymph node metastasis and distant 
metastasis. Conventionally, to control the local disease, therapy consists of a complete surgical 
resection of the tumor. This can be done by means of sphincter-sparing wide local excision or 
Abbreviations: ARMM, anorectal malignant melanomas; CM, central memory; ECOG, Eastern Cooperative Oncology 
Group; EM, effector memory; HPD, hyperprogressive disease; HD, healthy donor; HP patient, hyperprogressive patient; IMC, 
immature myeloid cells; Mono, monocytes; MDSC, myeloid-derived suppressor cells; PBMC, peripheral blood mononuclear 
cells; TEMRA, terminally differentiated effector memory RA+.
FIgURe 1 | Positron-emission tomography (PET)-scanner imaging at baseline (a) and after three cycles of pembrolizumab (B). (a) Patient’s baseline PET scan 
(December 2016): only four infracentimetric hypermetabolic lung nodules are visible [standardized uptake values (SUV) from 2.2 to 5.5]. No evidence of distant 
metastases elsewhere. (B) Patient’s PET scan after three cycles of pembrolizumab (May 2017): diffuse and multiple hypermetabolic lung, liver, subcutaneous tissue, 
and peritoneal lesions (SUV from 3.5 to 17).
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abdominoperineal resection (APR) (5). Radiotherapy may be 
used to enhance regional control but has no impact on overall 
survival (6). Because it is an aggressive malignancy, most patients 
become metastatic after a few months, and for decades, advanced 
ARMMs were commonly treated by systemic chemotherapies (7), 
such as cisplatine, vinblastine, and dacarbazine, or by immune 
agents such as interferon alpha-2b (IFN) and interleukin 2; 
however, these treatments have low effectiveness on response 
and survival.
Although conventional chemotherapies have shown only a 
minor benefit to patients with advanced melanoma (8), therapeu-
tic immune antibodies against programmed cell death receptor 
1 (PD-1) and programmed cell death receptor ligand 1 (PD-L1) 
have demonstrated a significant and durable response, either in 
front-line therapy or in subsequent therapies (9). However, the 
efficacy of PD-1 blockade in patients with biologically distinct 
melanomas arising from mucosal surfaces has not been well 
described, and data are still lacking (10).
Notably, anecdotal evidence of rapid disease progression in 
patients treated with anti-PD-1/anti-PD-L1 monoclonal anti-
bodies (mAbs) has been reported (11). This was shown by a 
French review of the tumor growth rates in 131 patients upon 
treatment with anti-PD-1 therapies, which revealed that 9% of 
patients developed hyperprogressive disease (HPD), character-
ized by accelerated tumor growth (12).
Here, we report a case of ARMM treated by a new immuno-
logic therapy PD-1 inhibitor, experiencing HPD over 2 months 
of treatment, leading to rapid death. We then present the HPD 
blood phenotype analysis and discussion.
Case RepoRt
A 77-year-old white male presented sporadic rectal bleeding in 
April 2016. Rectal examination revealed a mass in the lower rec-
tum. A broad-based rectal polyp measuring 10 mm and located 
approximately 6 cm from the anal verge was seen on colonoscopy, 
and a transanal polypectomy was performed. Histopathology 
diagnosed a 3.3-mm anorectal melanoma with positive stains 
for Melan A on immunohistochemistry, ulceration, high mitotic 
index, and inadequate positive resection margins (pT3bR1). 
Other malignant primary sites and distant metastases were 
ruled out. The patient underwent revised surgery that consisted 
of APR with bilateral inguinal lymphadenectomy, following the 
consensus of the interdisciplinary tumor board. Surgery and 
recovery were uneventful. The final tumor stage was pT3bN0 
(0/15) M0R0, stage IIb (UICC). No perineural invasion was 
revealed. Neither BRAF nor KIT mutations were identified on 
genetic analysis. No adjuvant treatment was given according to 
international guidelines. The follow-up consisted of alternately 
brain + thoraco–abdo–pelvic Computed Tomography (CT) and 
FIgURe 2 | Flow cytometry analysis of myeloid cells comparing the HP with five HD. (a) Higher proportion of monocytes (HLADR+ CD33+, CD14+) and CD16+ 
monocytes (HLADR+ CD33+, CD14+ CD16+) in HP compared to the HD (pro-inflammatory cells). (B) Increased median fluorescence intensity of PDL1 in monocytes/
CD16+ monocytes, and the more important percentage of the immunosuppressive population of Gr-MDSC in the HP patient compared to HD. Abbreviations: HP, 
hyperprogressive patient; HD, healthy donors; Mono, monocytes; Mono16+, monocytes 16+; GrMDSC, granulocytic myeloid-derived suppressor cells; Mo-MDSC, 
monocyte-derived suppressor cells; IMC, immature myeloid cells; PBMC, peripheral blood mononuclear cells.
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positron-emission tomography (PET) scan, every 3 months. Six 
months later, in December 2016, the thoracic CT scan revealed 
four new infracentimetric lung nodules that were confirmed 
to be hypermetabolic mild positive on PET scan (standardized 
uptake values from 2.2 to 5.5). There was no evidence of other 
extrapulmonary metastatic spreads (Figure 1A).
The patient was healthy with Eastern Cooperative Oncology 
Group 0 and no weight loss. As conventional chemotherapies are 
mostly inefficient, and based on encouraging results regarding 
patients with mucosal melanoma enrolled in first line therapy 
PD-1 inhibitor trials, a tumor board council validated a treatment 
course of pembrolizumab. The patient was given pembrolizumab 
200 mg IV, over 30 min, every 3 weeks (D1 = D21) from February 
to April 2017 (3 injections), with no specific side effects except 
for fatigue grade 1. However, in May 2017, the patient newly 
presented a right chest pain and a rapid deterioration of the gen-
eral status. A PET scan revealed the emergence of multiple new 
centimetric hypermetabolic lung spots along with increased size 
and glycolic activity in the previously identified nodules that were 
associated with multiple new hypermetabolic liver, subcutaneous 
tissues, and peritoneal lesions (Figure 1B), and showed a rapidly 
progressive disease over 2 months.
We performed blood tests to biologically document this 
hyperprogressive (HP) patient, but he refused new tumor biopsy. 
Immunophenotyping analyses by flow cytometry (BD Fortessa®/
FlowJo software®) were performed from peripheral blood mono-
nuclear cells (PBMC) based on a Ficoll density gradient after the 
third injection of pembrolizumab. As no other patient samples 
were available, we compared the sample to healthy donors (HD).
In the myeloid cells analysis presented in Figure  2, the HP 
patient had a higher proportion of monocytes (HLADR+ CD33+, 
CD14+) and CD16+ monocytes (HLADR+ CD33+, CD14+ CD16+) 
compared to the HD (Figure  2A). Furthermore, the patient’s 
monocytes and CD16+ monocytes had an increased median 
fluorescence intensity of PDL1 compared to HD. Additionally, 
between the live PBMC samples, the percentage of the immu-
nosuppressive population of granulocytic myeloid-derived sup-
pressor cells (Gr-MDSC), defined as CD33+/HLADR−/CD15+/
CD14−, was increased in the HP patient (Figure 2B).
In the lymphoid cell analysis presented in Figure 3, the HP 
patient presented a shift in CD4 and CD8 differentiation, with 
an increased proportion of CD4/CD8 naïve and CD4 terminally 
differentiated cells (TEMRA: Effector Memory CD45RA+), and 
a decrease in memory cells (central memory/effector memory). 
FIgURe 3 | Flow cytometry analysis of lymphoid T cells comparing the HP with five HD. HP showed an increased proportion of naïve CD4/CD8 and CD4 terminally 
differentiated cells (TEMRA: effector memory CD45RA+) and a decrease in memory cells (CM/EM). Abbreviations: HP, hyperprogressive patient; HD, healthy donors; 
CM, central memory; EM, Effector Memory; TEMRA, Terminally differentiated Effector Memory RA+.
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Among natural killer cells (NK  cells), the HP patient had an 
over-expression of NK bright (CD56+ high) cells and an under-
expression of the receptors NKp30 and NKp46 (Figure 4).
After three cycles of pembrolizumab, one cycle of salvage 
dacarbazine was given, but it did not bring any clinical impro-
vement. The patient was then treated with best supportive care 
on a palliative basis. He unfortunately passed away in July 2017.
DIsCUssIoN
In recent years, immunotherapy has revolutionized the standard of 
care of many solid tumors, especially melanomas, with a significant 
improvement in overall survival for some patients. Despite this 
progress, recent evidence suggests that treatment with PD-1 path-
way blockade therapy may backfire in a subset of patients, leading 
to rapid tumor development, a response opposite to that expected 
(13). HPD is related to a marked increase in the tumor growth 
kinetics (TGK) and defined by a ≥2-fold increase in the TGK 
ratio (TGK post treatment/TGK pretreatment), according to the 
Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (12).
Even though the precise frequency of hyperprogression is yet 
to be established, this topic is far from anecdotal; it concerns 9% 
(n = 12/132) of the multi-tumoral cohort of the Gustave Roussy 
Institute and 29% (n = 10/34) of a multicentric French cohort of 
head and neck carcinomas under anti PD-L1 therapy (11).
In this case study, initiation of immunotherapy in an elderly 
patient who had a slow-growing initial tumor led to HPD. These 
findings are consistent with emerging data from the literature 
where patients with HPD tend to be male, elderly, with low tumor 
volume and slow-growing initial disease at baseline (14).
The histological subtype does not seem to predict HPD since 
there is no difference in the rate of HPD across the different 
cancers pathologies including melanoma, urothelial, colorectal, 
ovarian, biliary tract carcinomas, and lymphoma (12). The num-
ber and type of previous lines of treatment, as well as PD1/PDL1 
expression, are not predictive factors for HPD (12).
Currently, the immunological basis of HPD is unknown. As 
this concept has been identified only recently, we are the first to 
describe the immunophenotyping of a patient with HPD. On the 
one hand, we have described in this patient an increase in pro-
inflammatory myeloid cells (monocytes and 16+ monocytes) and 
a hyperexpression of PDL1 that is coherent with an activated phe-
notype. Moreover, the presence in our patient of higher MDSC, 
known to be immunosuppressive due to its inhibitory effect on 
T  cell growth and functioning, could also partially explain the 
immunoevasion (15). On the other hand, the shift in the dif-
ferentiation of T cells in the blood (favoring naïve and TEMRA 
instead of memory cells) may be related to the tumoral trapping 
of CD4/CD8 memory cells or death due to hyper-stimulation. 
Altogether, these elements suggest that the patient is facing an 
inefficient inflammatory response rather than a tumoral-targeted 
T  cell response. As described previously in the literature, this 
patient may have had an imbalance between T cell reinvigoration 
and tumor burden (16).
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In this study, some limitations should be considered. First, the 
sample size was obviously small. Second, the dynamic changes in 
the levels of circulating cells before and after treatment is lacking, 
and basal samples should be collected in future studies, rather than 
using HD as a control. Third, as the patient refused a re-biopsy, 
we were not able to document the molecular or immunological 
changes of the tumor after HPD.
Finally, in the field of biomarkers, the clear challenges are to 
identify biomarkers that will be predictive of a positive clinical 
response to immunotherapy and target patients at risk of an HPD 
response, in addition to an age-dependent decrease in immuno-
logical competence.
For example, a recent study of 155 patients treated with anti-
PD-1/anti-PD-L1 therapy reported that all six individuals with 
MDM2/MDM4 amplification experienced time-to-treatment 
failure (TTF) of less than 2 months, and four of the six patients 
exhibited an HPD response (17). This study further showed that 
eight of 10 patients with EGFR mutations experienced TTF of less 
than 2 months, and 2 of 10 demonstrated HPD.
Interestingly, a recent research about anti-PD1 biomarkers using 
mass cytometry identified the frequency of CD14+ CD16− HLA-
DRhi monocytes in PBMC before therapy as the strongest predictor 
of response (18). Our findings, combined to this study, support 
the idea that monocytes are a key player in anti-PD1 response, 
notably because of their antigen-presenting functions on CD4/
CD8, and their possibility to differentiate into many different cells 
types (19). However, it is not clear if the dynamics of monocytes 
during anti-PD1 can predict outcome, and if PDL1 expression in 
monocytes leads to a functional impairment of CD8+ T cells (20).
Further investigations of the HPD response are still needed 
for the development of decision trees and to guide physicians’ 
choices to treat a patient with immunotherapies.
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FIgURe 4 | Flow cytometry analysis of NK cells comparing the HP with five HD. Increased proportion of NK bright (CD56+ high) cells in HP compared to HD. 
Conversely, decreased expression of the receptors NKp30 and NKp46 in HP compared to HD. Abbreviations: HP, hyperprogressive patient; HD, healthy donors; 
NKp30/NKp46, natural cytotoxicity receptors.
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